Retrospective cohort study observes real-world outcomes of isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma, highlighting early access program feasibility.
IMAGE is a retrospective cohort study of patients enrolled in early access programs (EAPs) in France with relapsed/refractory multiple myeloma (RRMM) receiving isatuximab with pomalidomide and dexamethasone (Isa-Pd).
No takes yet. Share an insight, caveat, or question.
Decaux et al. (2024) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: